Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Oligodendroglioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 9Specimen Handling 6Radiotherapy 6Magnetic Resonance Spectroscopy 6Radiation 5trametinib 2dabrafenib 2Radiotherapy, Intensity-Modulated 2Bevacizumab 2vorasidenib 1vocimagene amiretrorepvec 1veliparib 1trastuzumab deruxtecan 1ribociclib 1Vorinostat 1Spinal Puncture 1Protons 1Proton Therapy 1Pluvicto 1Nivolumab 1Magnetic Resonance Imaging 1Leukapheresis 1Irinotecan 1Ipilimumab 1Flucytosine 1Everolimus 1DNA 1Carmustine 1Carboplatin 1CTLA-4 Antigen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Astrocytoma × vocimagene amiretrorepvec × 30 days × Clear all
NCT04105374 2026-05-07

Testing the Addition of an Anti-cancer Viral Gene Therapy, Toca 511/Toca FC, to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed Glioblastoma

NRG Oncology

Phase 2/3 Withdrawn
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡